![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Onyx Pharmaceuticals, Inc. (MM) | NASDAQ:ONXX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 124.70 | 0 | 01:00:00 |
Third quarter 2012 loss of $0.89 per share was narrower than the Zacks Consensus Estimate of a loss of $1.08. Recently launched Kyprolis is off to a solid start and the strong ramp should continue.
Loss estimates for both 2012 and 2013 have gone down and the Zacks Rank has moved to #2 (short-term Buy rating) from 3 (short-term Hold rating). With two back-to-back product approvals to its credit, Onyx has successfully transformed itself from a one-product company to a multiple-product company.
ONYX PHARMA INC (ONXX): Free Stock Analysis Report
To read this article on Zacks.com click here.
1 Year Onyx Pharmaceuticals, Inc. (MM) Chart |
1 Month Onyx Pharmaceuticals, Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions